ANKRD22

Across TCGA pan-cancer cohorts, ANKRD22 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ANKRD22’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ANKRD22 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ANKRD22 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

COAD, PDAC, and LSCC are the cancer types where ANKRD22 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKRD22 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	+0.889	<.001	12	view →
PDAC	Female	II,III,IV	+1.544	<.001	10	view →
LSCC	Female	All	+1.270	<.001	9	view →
LUAD	All	II,III,IV	+1.026	<.001	9	view →
CCRCC	Male	II,III,IV	+0.494	<.001	9	view →
HNSC	All	IV	−0.519	.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ANKRD22–COAD

Open the COAD breakdown →